Founded in 1994, Beijing BGI-GBI Biotech Co., Ltd. (GBI) is the core subsidiary of BGI（SZSE Stock Code：300676） which is one of the largest genomic organizations in the world. GBI mainly focuses on the business including R&D, manufacture and sales of In Vitro Diagnostic (IVD) kits and clinical lab services. GBI is among the first batch of IVD enterprises who have obtained GMP certificate in China. All the blood-screening products have 100% passed inter-batch inspection of National Medical Product Administration (NMPA) for over 20 years in a row, and GBI has repeatedly ranked first with full marks in clinical quality assessment organized by the National Center for Disease Control and Prevention (NCDCP).
To improve people's health, we innovate medical detection model and enhance the efficiency of diagnosis and treatment. GBI is one of IVD enterprises which possesses the most comprehensive platforms. So far GBI has established methodological platforms such as mass spectrometry, nucleic acid testing, ELISA, CLIA, CMIA, POCT, gene sequencing and so on covering fields like reproductive health, cancer screening and medication, regular diseases, infectious diseases, blood screening, and nutrition detection. We have independently developed more than 100 categories of diagnostic kits approved by NMPA and have obtained EU-CE Markings for most products. In 2018, GBI undertook National S&T Major Project of China and One Belt One Road national research task. We have deep cooperation with hospitals in China, and we are also one of the largest reagent suppliers of large-scale physical examinations and healthcare centers. Not only have we focused on people's livelihood for a long run, GBI has also played an important role in providing aids against major disasters such as SARS, H1N1, and COVID-19.